Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib-Reference-Cited by-同舟云学术

Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G796S/R) together with C797S/G and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib

Published:2017-06 Issue: Volume:108 Page:228-231
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Ou Sai-Hong Ignatius,Cui Jean,Schrock Alexa B.,Goldberg Michael E.,Zhu Viola W.,Albacker Lee,Stephens Philip J.,Miller Vincent A.,Ali Siraj M.

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference18 articles.

1. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer;Cross;Cancer Discov.,2014

2. Osimertinib for the treatment of metastatic epidermal growth factor T970M positive non-small cell lung cancer;Khozin;Clin. Cancer Res.,2016

3. Osimertinib or platinum-pemetrexed in EGFR T790M- positive lung cancer;Mok;N. Engl. J. Med.,2016

4. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping;Ou;J. Thorac. Oncol.,2017

5. Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M;Thress;Nat. Med.,2015

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Mechanisms of resistance to tyrosine kinase inhibitor‐targeted therapy and overcoming strategies;MedComm;2024-08-24

2. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

3. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges;Frontiers in Immunology;2024-04-09

4. Non-small cell lung cancer: an update on emerging EGFR-targeted therapies;Expert Opinion on Emerging Drugs;2024-04-02

5. The study of primary and acquired resistance to first-line osimertinib to improve the outcome of EGFR-mutated advanced Non-small cell lung cancer patients: the challenge is open for new therapeutic strategies;Critical Reviews in Oncology/Hematology;2024-04